Scarica l'app Stockscreener
281.10
3.62%
9.82
Pre-mercato:
279.45
-1.65
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$271.28
Aprire:
$275.7
Volume 24 ore:
1.72M
Relative Volume:
0.96
Capitalizzazione di mercato:
$54.69B
Reddito:
$328.68B
Utile/perdita netta:
$2.55B
Rapporto P/E:
21.57
EPS:
13.0349
Flusso di cassa netto:
$1.56B
1 W Prestazione:
-0.13%
1M Prestazione:
+2.25%
6M Prestazione:
-17.47%
1 anno Prestazione:
-4.10%
Intervallo 1D:
$274.38
$283.76
Intervallo di 1 settimana:
$269.30
$283.76
Portata 52W:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Nome
Cencora Inc
Settore
Industria
Telefono
610-727-7000
Indirizzo
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
281.10 | 54.69B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
763.91 | 89.44B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
228.91 | 53.61B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
80.10 | 9.12B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.36 | 1.17B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Ripresa | Mizuho | Outperform |
| 2024-09-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-03 | Iniziato | Barclays | Overweight |
| 2023-12-14 | Iniziato | Wells Fargo | Equal Weight |
| 2023-03-31 | Iniziato | Citigroup | Buy |
| 2023-01-31 | Ripresa | Evercore ISI | Outperform |
| 2022-10-11 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Ripresa | Evercore ISI | In-line |
| 2021-02-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-01-06 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Iniziato | Mizuho | Neutral |
| 2020-08-06 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Iniziato | Barclays | Underweight |
| 2020-06-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Ripresa | Credit Suisse | Outperform |
| 2020-04-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-11 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Iniziato | Deutsche Bank | Hold |
| 2019-07-10 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Iniziato | Guggenheim | Buy |
| 2019-04-10 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Iniziato | UBS | Buy |
| 2018-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2018-10-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Iniziato | Berenberg | Buy |
| 2018-07-17 | Ripresa | Stifel | Hold |
| 2018-04-09 | Iniziato | MoffettNathanson | Buy |
| 2018-03-12 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Iniziato | JP Morgan | Neutral |
| 2017-09-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Cencora Inc Borsa (COR) Ultime notizie
A Look at Cencora Inc (COR) After 3.6% Gain -- GF Value $291.84 vs Price $281.10 - GuruFocus
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora insider buying draws attention, shares trade higher on NYSE - Ad-hoc-news.de
Cencora Inc (COR) Institutional Confidence - TradingKey
Insider Buying: Dermot Durcan Acquires Additional Shares of Cenc - GuruFocus
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks By Investing.com - Investing.com Australia
Ambetter Health Virtual Access from Centene Corp.subscription care with $0 virtual visits - Ad-hoc-news.de
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks - Investing.com Australia
ICS from Cencora Inc.digital medication cabinets for busy hospital wards - Ad-hoc-news.de
Cencora (COR) director adds 4,000 shares in open-market stock purchase - Stock Titan
Cencora sets July management change, shares under revised Barclays target - Ad-hoc-news.de
Pharmagen from Cencora Inc.specialty generics with a hospital focus - Ad-hoc-news.de
Cencora, Inc. (COR) Stock Analysis: Understanding Its 28.97% Upside Potential - DirectorsTalk Interviews
Cencora Inc (COR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Are Wall Street analysts bullish on Cencora stock? - MSN
Centene StockVoluntary employee buyouts sharpen long-term cost focus - Ad-hoc-news.de
Why Centene’s Wellcare Medicare Advantage plans matter for seniors - AD HOC NEWS
CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026? - TradingView
Cencora Inc. stock underperforms Thursday when compared to competitors - MarketWatch
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell? - TradingView
Why Cencora’s Fusion Center keeps specialty drugs flowing quietly in the background - AD HOC NEWS
Cencora Launches Enhanced Nucleus Solution for Specialty Practices - Yahoo Finance
Cencora Inc (COR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cencora Inc (COR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cencora Inc (COR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cencora Inc (COR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cencora Inc (COR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cencora Inc (COR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Frontier Mid Cap Growth Portfolio's Cencora Inc(COR) Holding History - GuruFocus
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices - Business Wire
Cencora (COR) Stock Could Be 20% Below Fair Value On Margin Growth Narrative - simplywall.st
Deals tracker: Baptist Health acquires Arkansas hospital - Modern Healthcare
Cencora Connect Pro platform launches to streamline specialty drug distribution - AD HOC NEWS
Cencora, Inc. (COR) Announces Executive Leadership Transition - GuruFocus
Cencora (COR) Announces Executive Transition in Human Resources - GuruFocus
Eva Boratto resigns from UPS board following appointment at Cencora By Investing.com - Investing.com Australia
Eva Boratto resigns from UPS board following appointment at Cencora - Investing.com
Cencora (NYSE: COR) taps Samantha Hammock as new Chief HR Officer - Stock Titan
Flagship logistics upgrade: Cencora’s Fusion Center platform scales real-time pharma visibility - AD HOC NEWS
Cencora, Inc. (COR) Stock Analysis: Exploring a 24% Potential Upside in Healthcare Distribution - DirectorsTalk Interviews
Is Cencora stock underperforming the Nasdaq? - MSN
Cencora Inc. Stock (US15135B1017): Valuation metrics in focus after steady share price climb - AD HOC NEWS
Cencora (COR) Q2 2026 Earnings Call Transcript - Fortune
Cencora Inc Stock (US03073E1055): Analyst Rating In Focus After Barclays Cuts Target - AD HOC NEWS
The Profit Margin Climb Cencora Stock Bears Keep Missing - Trefis
Cencora Drug Distribution Story Gains Healthcare Market Attention - Kalkine Media
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential - Yahoo Finance
Barclays Cuts Cencora Price Target to $350 From $425, Maintains Overweight Rating - marketscreener.com
Central Garden & Pet stock (US15135B1017): earnings momentum and pet-care demand in focus - AD HOC NEWS
What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders - simplywall.st
Cencora Inc Azioni (COR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.77%
2.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):